The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant.
about
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patientsDrug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD.Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells.Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma.Prognostic value and efficacy evaluation of novel drugs for cytogenetic aberrations in multiple myeloma: a meta-analysis.Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma.Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsGenetics of multiple myeloma: another heterogeneity level?Genetic heterogeneity in multiple myeloma.A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.Advances in the management of myeloma.Genetic events in the pathogenesis of multiple myeloma.Clinical implications of chromosomal abnormalities in multiple myeloma.Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.Genetic aberrations in multiple myeloma characterized by cIg-FISH: a Brazilian context.Review of molecular diagnostics in multiple myeloma.Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012Genomics in multiple myeloma.The genetic architecture of multiple myeloma.Clinical impact of chromosomal aberrations in multiple myeloma.Genomic stratification of multiple myeloma treated with novel agents.Understanding the molecular biology of myeloma and its therapeutic implications.Staging and prognostication of multiple myelomaAssociation of Chromosomal Translocation and MiRNA Expression with The Pathogenesis of Multiple Myeloma.Current and potential epigenetic targets in multiple myeloma.Controversies in multiple myeloma: to transplant or not?Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence.Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy.MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.Genomic Aberrations in Multiple Myeloma.Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial.The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressorMB4-2/MB4-3 transcripts of IGH-MMSET fusion gene in t(4;14)pos multiple myeloma indicate poor prognosis.Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution.
P2860
Q24670250-9FA8E113-9E0B-4A42-8E28-2294EDE1A1D2Q27692033-3E5F6834-3001-4AF9-B9D2-2E07C4A6B6F8Q31154933-E5BBB2C8-75FD-4EA2-A254-60BD03640C1FQ33369092-0D9B77A7-99AA-4AE9-8627-C343C3FFA407Q33846310-7F268FDA-07C6-448A-8E48-46CDFDCB0C09Q33948015-45AA1C1E-44AC-49C8-A6A1-60665D616908Q33952805-5C98618A-E96A-4CF7-84F8-2FEA7ADB0FA0Q34241661-D60C5E60-0197-4BC2-959A-0ADCB65891FFQ34296442-8ADDE4B8-31CB-4844-A9BE-15DC1B6573D2Q34769841-0E322BE8-ADF3-4177-9FA6-630FAF110B70Q34993904-ED1CEC7A-68B3-41C1-9E9C-BF023AA3210AQ35081172-2FFA8953-CCCE-457A-9836-2C9CF524D44FQ35197437-89D11B09-C60D-4563-950E-EE3C91852F1FQ35945858-79EC8FDC-E08D-4F67-B8D5-56DB64A7D6E4Q35984702-D7E845D8-16AA-4443-98E8-03DFC479042CQ36174361-B3478DC4-F61A-4E9B-8178-45BB5F2ABB4AQ36380235-6879677F-4FAE-49F7-AF1F-074E7425E7AAQ36497416-82785C50-EBF1-4892-AB4B-6ADF3A18FD16Q36595290-F06F5DA4-89E6-461C-8329-BD30DDD6CF11Q36654607-6111F176-1646-46DE-8ED9-5371A433D5B3Q36793582-6FFC49AD-0740-47C8-BBD4-7790DFC125B2Q36874362-4CFF90DA-9BF8-4F37-8439-DE536D062FFDQ37057028-C7CAD100-2884-4539-9E9F-986548662C54Q37197359-B4AD728C-C38C-45C4-9146-7A402507EEF8Q37718836-A8DD0FB2-BE41-4795-98A2-EFBF55D103FCQ37821077-6563AE23-2E90-4EB4-88AA-FC54370DA709Q37913346-08464949-2D93-4B7E-9A17-690354A4973BQ38065305-2CDCD3F3-0F99-4771-9DCC-C794A4BFF15FQ38183871-C7F6151E-6D78-443C-B2F3-2B93025F4428Q38190971-D26DD169-8351-4B8D-ABAA-134D509C5368Q38210475-D3D8553C-59C8-440C-A17E-792FA42B552BQ38242006-A5A58D6C-54AD-47FC-BAC0-B8D945199360Q38436315-5F5EA91C-0878-48C0-A2A4-940AAEBC9809Q38617375-EEEC08A3-5BEB-43E3-909A-C46B253E61E2Q38850840-55956A21-D718-4CD5-A388-9FAE89259C33Q38970573-C0773595-4F11-4F89-A98B-BA056AA69078Q39397389-C8582DB7-2193-4BCE-8864-E5593DA036FCQ40031496-C404092E-001E-46FA-8225-644992132F3AQ41612914-47FCA349-B16D-42DF-9D56-6CC7C558EF7BQ41853364-FCBDB41D-02CB-426A-9355-05F9E9ECC728
P2860
The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
The t(4;14) is associated with ...... tologous stem cell transplant.
@en
type
label
The t(4;14) is associated with ...... tologous stem cell transplant.
@en
prefLabel
The t(4;14) is associated with ...... tologous stem cell transplant.
@en
P2093
P2860
P1476
The t(4;14) is associated with ...... tologous stem cell transplant.
@en
P2093
A Keith Stewart
Christine I Chen
Donna Reece
Hong Chang
Kathy Chun
Lihua Zhuang
Qi-Long Yi
Stephen Sloan
P2860
P356
10.1111/J.1365-2141.2004.04867.X
P407
P577
2004-04-01T00:00:00Z